Source / episode info
- **Episode:**452
- **Title:**Divine Intervention Episode 452: NMS and Malignant Hyperthermia (vs Serotonin Syndrome)
- **Published:**2023-04-18
- Source:Episode page
One-liner
This episode compares Neuroleptic Malignant Syndrome (NMS) and Malignant Hyperthermia (MH), both presenting with rigidity and hypermetabolic states, while contrasting them sharply with Serotonin Syndrome (SS) based on underlying triggers, specific lab abnormalities ({K}^{+}, {PO}_{4}^{3-}), and neuromuscular signs (rigidity vs. hyperreflexia).
High-yield summary
- NMS: Characterized by severe muscle rigidity, altered mental status, fever, and lactic acidosis; often triggered by D2 receptor antagonists (anti-psychotics) or withdrawal of dopamine agonists.
- MH: A genetically inherited condition involving a mutation in the ryanodine receptor ({Ca}^{2+} channel); triggered by volatile anesthetics (e.g., sevoflurane, halothane) or succinylcholine; leads to massive {Ca}^{2+} release and hypermetabolism.
- MH Lab Triad: Due to muscle breakdown (rhabdomyolysis), MH patients often present with hyperkalemia, hyperphosphatemia, and subsequent hypocalcemia.
- Differential Diagnosis: The key differentiator is neuromuscular signs: NMS/MH cause rigidity and hypokinesis, whereas Serotonin Syndrome causes hyperreflexia and clonus.
- Treatment Cornerstone: Both MH and NMS can be treated with a ryanodine receptor antagonist, Dantrolene, which inhibits excessive calcium release.
Learning objectives
- Differentiate the clinical presentation (neuromuscular signs, lab abnormalities) among NMS, MH, and SS.
- Identify the specific triggers for Malignant Hyperthermia (volatile anesthetics, succinylcholine).
- Understand the underlying molecular defect in MH related to the ryanodine receptor.
- Recognize that dopamine agonists are both a potential cause and sometimes a treatment for NMS.
- Correlate muscle breakdown products (\text{K}^{+}, \text{PO}_{4}^{3-}, myoglobin) with severe hypermetabolic states like MH.
Board exam buzzwords